Market Research Life Sciences Market Research Pharmaceuticals Market Research Drug Discovery Market Research

Gout Market Research Report Forecast till 2030

Best Price Guarantee Length Publisher Published Date SKU
from $4,950 128 Pages Market Research Future November, 2023 RESFT18286569
Best Price Guarantee
Price from $4,950
Length 128 Pages
Publisher Market Research Future
Published Date November, 2023
SKU RESFT18286569

Gout Market Research Report Forecast till 2030


Gout Market is anticipated to register a significant CAGR of 11.75% during the review period.

Gout is a kind of provocative joint pain that influences men beyond 40 a year old, have a high measure of uric corrosive in their blood. As per studies, its commonness and frequency have expanded over the most recent couple of many years. The rising commonness of gout because of changing way of life designs and the developing geriatric populace is supposed to help market development over the gauge period. For example, according to the article distributed by the Records of Rheumatic Sicknesses in June 2021, a cross country companion concentrates on utilizing information from the Clinical Practice Research Datalink, from 1997 to across the Coronavirus pandemic in 2021 saw that the predominance pace of gout has expanded from 0.98%in 1997 to 2.33% in 2021. Notwithstanding, as per a similar source, the frequency of gout expanded by 0.98/1,000 people in UK 2021. Thusly, the weight of gout is supposed to build the interest in drugs treating this condition, which is expected to impel the market development over the estimate period.

Market Segmentation
The Gout Market segmentation, based on treatment and diagnosis, includes diagnosis, treatment. The treatment segment is further sub segmented into NSAIDs, corticosteroids, colchicine, urate-lowering agents, and others.
The Gout Market segmentation is based on applications that include acute gout and chronic gout. The Gout Market segmentation is based on hospitals & clinics, specialty centers, and others.

Regional Insights
The North America region fragmented into US, and Canada. The North America region held the biggest market share in the Gout Endlessly market is represented USD 1.80 billion of every 2022 and is supposed to display a 12.03% CAGR during the review time frame. Further, in the North America region the US gout market represented the biggest market share. This is credited to the rising predominance of gout, developing reception of biologics, and rising Research and development exercises on regenerative prescriptions.

Europe gout market is supposed to represent the second-biggest market share because of the availability to cutting edge finding and treatment offices, the rising geriatric populace inclined to gout is driving up interest for powerful treatment and therapeutics and developing medical care consumption. The Asia-Pacific gout market is supposed to develop at a CAGR of 13.12% from 2023 to 2030. This is because of variables like further developing medical care framework, developing speculation by central parts with neighbourhood producers, and the rising patient populace experiencing gout.

The Rest of the World incorporates the Middle East, Africa, and Latin America. Middle East hold the significant market share in middle east and Africa region because of restricted medical care framework, a shortage of mindfulness regarding the side effects of the sickness, and an absence of talented experts to make gout therapeutics drugs are restricting the development of the gout market in Sub-Saharan Africa.

Major Players
Key Companies in the Gout Market are Novartis AG (Switzerland), Lannett (US), Horizon Therapeutics plc (US), Takeda Pharmaceutical Company Limited (Japan), GlaxoSmithKline plc (UK), Regeneron Pharmaceuticals, Inc (US), Teijin Limited (Japan), Viatris Inc (US), Boehringer Ingelheim International GmbH (Germany), and ROMEG Therapeutics, LLC (US).

Companies Mentioned
Novartis AG (Switzerland)
Lannett (US)
Horizon Therapeutics plc (US)
Takeda Pharmaceutical Company Limited (Japan)
GlaxoSmithKline plc (UK)
Regeneron Pharmaceuticals Inc (US)
Teijin Limited (Japan)
Viatris Inc (US)
Boehringer Ingelheim International GmbH (Germany)
and ROMEG Therapeutics
LLC (US)

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.


1 Executive Summary 13
1.1 Overview 13
2 Market Introduction 14
2.1 Definition 14
2.2 Scope Of The Study 14
2.3 Research Objective 14
2.4 Market Structure 15
2.5 Assumptions & Limitations 15
3 Research Methodology 16
3.1 Data Mining 16
3.2 Secondary Research 17
3.3 Primary Research 18
3.4 Breakdown Of Primary Respondents 19
3.5 Forecasting Techniques 20
3.6 Research Methodology For Market Size Estimation 21
3.6.1 Bottom-up Approach 22
3.6.2 Top-down Approach 22
3.7 Data Triangulation 23
3.8 Validation 23
4 Market Dynamics 24
4.1 Overview 24
4.2 Drivers 25
4.2.1 Increasing Prevalence Of Gout 25
4.2.2 Rising Healthcare Expenditure 25
4.2.3 Increasing Research And Development Activities 26
4.3 Restraints 27
4.3.1 Side Effects Of Gout Therapeutic Drugs 27
4.3.2 Lack Of Awareness Among People 28
4.4 Opportunity 28
4.4.1 Rising Number Of Strategic Initiatives 28
5 Market Factor Analysis 29
5.1 Value Chain Analysis 29
5.1.1 R&D 30
5.1.2 Manufacturing 30
5.1.3 Distribution & Sales 30
5.1.4 Post-sales Monitoring 30
5.2 Porter's Five Forces Model 31
5.2.1 Threat Of New Entrants 31
5.2.2 Bargaining Power Of Suppliers 32
5.2.3 Threat Of Substitutes 32
5.2.4 Bargaining Power Of Buyers 32
5.2.5 Intensity Of Rivalry 32
5.3 Impact Of Covid-19 On The Global Gout Market 33
5.3.1 Impact On Value Chain 33
5.3.2 Impact On Supply Chain 33
5.3.3 Impact On Key Players 33
6 Global Gout Market, By Diagnosis & Treatment 34
6.1 Overview 34
6.2 Diagnosis 36
6.3 Treatment 36
6.3.1 Nsaids 37
6.3.2 Corticosteroids 37
6.3.3 Colchicine 38
6.3.4 Urate-lowering Agents 38
6.3.5 Others 39
7 Global Gout Market, By Application 40
7.1 Overview 40
7.2 Acute Gout 41
7.3 Chronic Gout 42
8 Global Gout Market, By End User 43
8.1 Overview 43
8.2 Hospitals & Clinics 44
8.3 Specialty Centers 45
8.4 Others 45
9 Global Gout Market, By Region 46
9.1 Overview 46
9.2 North America 48
9.2.1 Us 50
9.2.2 Canada 51
9.3 Europe 52
9.3.1 Germany 54
9.3.2 Uk 55
9.3.3 France 56
9.3.4 Italy 57
9.3.5 Spain 58
9.3.6 Rest Of Europe 59
9.4 Asia-pacific 61
9.4.1 China 63
9.4.2 Japan 64
9.4.3 India 65
9.4.4 Australia 66
9.4.5 South Korea 67
9.4.6 Rest Of Asia Pacific 68
9.5 Rest Of The World 69
9.5.1 Middle East 71
9.5.2 Africa 72
9.5.3 Latin America 73
10 Competitive Landscape 74
10.1 Overview 74
10.2 Competitive Benchmarking 75
10.3 Major Growth Strategy In The Global Gout Market 76
10.4 The Leading Player In Terms Of The Number Of Developments In The Global Gout Market 77
10.5 Key Development Analysis 77
10.6 Key Developments & Growth Strategies 78
10.6.1 Product Launch/ Product Approval 78
10.6.2 Partnerships/ Agreements 78
10.7 Financial Matrix 78
10.7.1 Sales (Usd Million), 2022 78
10.7.2 Research & Development Expenditure (Usd Million), 2022 79
11 Company Profiles 80
11.1 Novartis Ag 80
11.1.1 Company Overview 80
11.1.2 Financial Overview 81
11.1.3 Products Offered 81
11.1.4 Key Developments 81
11.1.5 Swot Analysis 82
11.1.6 Key Strategies 82
11.2 Lannett 83
11.2.1 Company Overview 83
11.2.2 Financial Overview 83
11.2.3 Products Offered 84
11.2.4 Key Developments 84
11.2.5 Key Strategies 84
11.3 Horizon Therapeutics Plc 85
11.3.1 Company Overview 85
11.3.2 Financial Overview 86
11.3.3 Products Offered 86
11.3.4 Key Developments 86
11.3.5 Key Strategies 87
11.4 Takeda Pharmaceutical Company Limited 88
11.4.1 Company Overview 88
11.4.2 Financial Overview 88
11.4.3 Products Offered 89
11.4.4 Key Developments 89
11.4.5 Key Strategies 89
11.5 Glaxosmithkline Plc 90
11.5.1 Company Overview 90
11.5.2 Financial Overview 91
11.5.3 Products Offered 91
11.5.4 Key Developments 91
11.5.5 Swot Analysis 92
11.5.6 Key Strategies 92
11.6 Regeneron Pharmaceuticals, Inc. 93
11.6.1 Company Overview 93
11.6.2 Financial Overview 93
11.6.3 Products Offered 94
11.6.4 Key Developments 94
11.6.5 Key Strategies 94
11.7 Teijin Limited 95
11.7.1 Company Overview 95
11.7.2 Financial Overview 95
11.7.3 Products Offered 96
11.7.4 Key Developments 96
11.7.5 Swot Analysis 96
11.7.6 Key Strategies 96
11.8 Viatris Inc. 97
11.8.1 Company Overviews 97
11.8.2 Financial Overview 98
11.8.3 Products Offered 98
11.8.4 Key Developments 98
11.8.5 Swot Analysis 99
11.8.6 Key Strategies 99
11.9 Boehringer Ingelheim International Gmbh. 100
11.9.1 Company Overview 100
11.9.2 Financial Overview 101
11.9.3 Products Offered 101
11.9.4 Key Developments 102
11.9.5 Swot Analysis 102
11.9.6 Key Strategies 102
11.10 Romeg Therapeutics, Llc 103
11.10.1 Company Overview 103
11.10.2 Financial Overview 103
11.10.3 Products Offered 103
11.10.4 Key Developments 103
11.10.5 Key Strategies 103
12 Appendix 104
12.1 References 104
12.2 World Health Organization 104
12.3 The Gout Education Society 104
12.4 Arthritis Foundation 104
12.5 American Arthritis Society 104
12.6 South African Rheumatism And Arthritis Association (Saraa) 104
12.7 Emirates Arthritis Foundation 104
12.8 Arthritis Foundation Of Asia 104
12.9 Osteoarthritis Research Society International (Oarsi) 104
12.10 Soar - Society For Osteoarthritis Research 104
12.11 The European Alliance Of Associations For Rheumatology 104
12.12 Related Reports 105
List Of Tables
Table 1 List Of Assumptions & Limitations 15
Table 2 Primary Interviews And Information Gathering Process 18
Table 3 Global Gout Market, By Diagnosis And Treatment, 2018–2030 (Usd Million) 35
Table 4 Global Gout Market, For Diagnosis, By Region, 2018–2030 (Usd Million) 36
Table 5 Global Gout Market, For Treatment, By Region, 2018–2030 (Usd Million) 36
Table 6 Global Gout Market, For Nsaids, By Region, 2018–2030 (Usd Million) 37
Table 7 Global Gout Market, For Corticosteroids, By Region, 2018–2030 (Usd Million) 37
Table 8 Global Gout Market, For Colchicine, By Region, 2018–2030 (Usd Million) 38
Table 9 Global Gout Market, For Urate-lowering Agents, By Region, 2018–2030 (Usd Million) 38
Table 10 Global Gout Market, For Others, By Region, 2018–2030 (Usd Million) 39
Table 11 Global Gout Market, By Application, 2018–2030 (Usd Million) 41
Table 12 Global Gout Market, For Acute Gout, By Region, 2018–2030 (Usd Million) 41
Table 13 Global Gout Market, For Chronic Gout, By Region, 2018–2030 (Usd Million) 42
Table 14 Global Gout Market, By End User, 2018–2030 (Usd Million) 44
Table 15 Global Gout Market, For Hospitals & Clinics, By Region, 2018–2030 (Usd Million) 44
Table 16 Global Gout Market, For Specialty Centers, By Region, 2018–2030 (Usd Million) 45
Table 17 Global Gout Market, For Others, By Region, 2018–2030 (Usd Million) 45
Table 18 Global: Gout Market, By Region, 2018–2030 (Usd Million) 46
Table 19 North America: Gout Market, By Country, 2018-2030 (Usd Million) 48
Table 20 North America: Gout Market, By Treatment And Diagnosis, 2018-2030 (Usd Million) 49
Table 21 North America: Gout Market, By Treatment, 2018-2030 (Usd Million) 49
Table 22 North America: Gout Market, By Application, 2018-2030 (Usd Million) 49
Table 23 North America: Gout Market, By End User, 2018-2030 (Usd Million) 49
Table 24 Us: Gout Market, By Treatment And Diagnosis, 2018-2030 (Usd Million) 50
Table 25 Us: Gout Market, By Treatment, 2018-2030 (Usd Million) 50
Table 26 Us: Gout Market, By Application, 2018-2030 (Usd Million) 50
Table 27 Us: Gout Market, By End User, 2018-2030 (Usd Million) 50
Table 28 Canada: Gout Market, By Treatment And Diagnosis, 2018-2030 (Usd Million) 51
Table 29 Canada: Gout Market, By Treatment, 2018-2030 (Usd Million) 51
Table 30 Canada: Gout Market, By Application, 2018-2030 (Usd Million) 51
Table 31 Canada: Gout Market, By End User, 2018-2030 (Usd Million) 51
Table 32 Europe: Gout Market, By Country, 2018–2030 (Usd Million) 53
Table 33 Europe: Gout Market, By Treatment And Diagnosis, 2018-2030 (Usd Million) 53
Table 34 Europe: Gout Market, By Treatment, 2018-2030 (Usd Million) 53
Table 35 Europe: Gout Market, By Application, 2018-2030 (Usd Million) 54
Table 36 Europe: Gout Market, By End User, 2018-2030 (Usd Million) 54
Table 37 Germany: Gout Market, By Treatment And Diagnosis, 2018-2030 (Usd Million) 54
Table 38 Germany: Gout Market, By Treatment, 2018-2030 (Usd Million) 54
Table 39 Germany: Gout Market, By Application, 2018-2030 (Usd Million) 55
Table 40 Germany: Gout Market, By End User, 2018-2030 (Usd Million) 55
Table 41 Uk: Gout Market, By Treatment And Diagnosis, 2018-2030 (Usd Million) 55
Table 42 Uk: Gout Market, By Treatment, 2018-2030 (Usd Million) 55
Table 43 Uk: Gout Market, By Application, 2018-2030 (Usd Million) 56
Table 44 Uk: Gout Market, By End User, 2018-2030 (Usd Million) 56
Table 45 France: Gout Market, By Treatment And Diagnosis, 2018-2030 (Usd Million) 56
Table 46 France: Gout Market, By Treatment, 2018-2030 (Usd Million) 56
Table 47 France: Gout Market, By Application, 2018-2030 (Usd Million) 57
Table 48 France: Gout Market, By End User, 2018-2030 (Usd Million) 57
Table 49 Italy: Gout Market, By Treatment And Diagnosis, 2018-2030 (Usd Million) 57
Table 50 Italy: Gout Market, By Treatment, 2018-2030 (Usd Million) 57
Table 51 Italy: Gout Market, By Application, 2018-2030 (Usd Million) 58
Table 52 Italy: Gout Market, By End User, 2018-2030 (Usd Million) 58
Table 53 Spain: Gout Market, By Treatment And Diagnosis, 2018-2030 (Usd Million) 58
Table 54 Spain: Gout Market, By Treatment, 2018-2030 (Usd Million) 58
Table 55 Spain: Gout Market, By Application, 2018-2030 (Usd Million) 59
Table 56 Spain: Gout Market, By End User, 2018-2030 (Usd Million) 59
Table 57 Rest Of Europe: Gout Market, By Treatment And Diagnosis, 2018-2030 (Usd Million) 59
Table 58 Rest Of Europe: Gout Market, By Treatment, 2018-2030 (Usd Million) 59
Table 59 Rest Of Europe: Gout Market, By Application, 2018-2030 (Usd Million) 60
Table 60 Rest Of Europe: Gout Market, By End User, 2018-2030 (Usd Million) 60
Table 61 Asia-pacific: Gout Market, By Country, 2018–2030 (Usd Million) 61
Table 62 Asia-pacific: Gout Market, By Treatment And Diagnosis, 2018–2030 (Usd Million) 62
Table 63 Asia-pacific: Gout Market, By Treatment, 2018–2030 (Usd Million) 62
Table 64 Asia-pacific: Gout Market, By Application, 2018–2030 (Usd Million) 62
Table 65 Asia-pacific: Gout Market, By End User, 2018–2030 (Usd Million) 62
Table 66 China: Gout Market, By Treatment And Diagnosis, 2018–2030 (Usd Million) 63
Table 67 China: Gout Market, By Treatment, 2018–2030 (Usd Million) 63
Table 68 China: Gout Market, By Application, 2018–2030 (Usd Million) 63
Table 69 China: Gout Market, By End User, 2018–2030 (Usd Million) 63
Table 70 Japan: Gout Market, By Treatment And Diagnosis, 2018–2030 (Usd Million) 64
Table 71 Japan: Gout Market, By Treatment, 2018–2030 (Usd Million) 64
Table 72 Japan: Gout Market, By Application, 2018–2030 (Usd Million) 64
Table 73 Japan: Gout Market, By End User, 2018–2030 (Usd Million) 64
Table 74 India: Gout Market, By Treatment And Diagnosis, 2018–2030 (Usd Million) 65
Table 75 India: Gout Market, By Treatment, 2018–2030 (Usd Million) 65
Table 76 India: Gout Market, By Application, 2018–2030 (Usd Million) 65
Table 77 India: Gout Market, By End User, 2018–2030 (Usd Million) 65
Table 78 Australia: Gout Market, By Treatment And Diagnosis, 2018–2030 (Usd Million) 66
Table 79 Australia: Gout Market, By Treatment, 2018–2030 (Usd Million) 66
Table 80 Australia: Gout Market, By Application, 2018–2030 (Usd Million) 66
Table 81 Australia: Gout Market, By End User, 2018–2030 (Usd Million) 66
Table 82 South Korea: Gout Market, By Treatment And Diagnosis, 2018–2030 (Usd Million) 67
Table 83 South Korea: Gout Market, By Treatment, 2018–2030 (Usd Million) 67
Table 84 South Korea: Gout Market, By Application, 2018–2030 (Usd Million) 67
Table 85 South Korea: Gout Market, By End User, 2018–2030 (Usd Million) 67
Table 86 Rest Of Asia Pacific: Gout Market, By Treatment And Diagnosis, 2018–2030 (Usd Million) 68
Table 87 Rest Of Asia Pacific: Gout Market, By Treatment, 2018–2030 (Usd Million) 68
Table 88 Rest Of Asia Pacific: Gout Market, By Application, 2018–2030 (Usd Million) 68
Table 89 Rest Of Asia Pacific: Gout Market, By End User, 2018–2030 (Usd Million) 68
Table 90 Rest Of The World: Gout Market, By Country, 2018–2030 (Usd Million) 69
Table 91 Rest Of The World: Gout Market, By Treatment And Diagnosis, 2018–2030 (Usd Million) 70
Table 92 Rest Of The World: Gout Market, By Treatment, 2018–2030 (Usd Million) 70
Table 93 Rest Of The World: Gout Market, By Application, 2018–2030 (Usd Million) 70
Table 94 Rest Of The World: Gout Market, By End User, 2018–2030 (Usd Million) 70
Table 95 Middle East: Gout Market, By Treatment And Diagnosis, 2018–2030 (Usd Million) 71
Table 96 Middle East: Gout Market, By Treatment, 2018–2030 (Usd Million) 71
Table 97 Middle East: Gout Market, By Application, 2018–2030 (Usd Million) 71
Table 98 Middle East: Gout Market, By End User, 2018–2030 (Usd Million) 71
Table 99 Africa: Gout Market, By Treatment And Diagnosis, 2018–2030 (Usd Million) 72
Table 100 Africa: Gout Market, By Treatment, 2018–2030 (Usd Million) 72
Table 101 Africa: Gout Market, By Application, 2018–2030 (Usd Million) 72
Table 102 Africa: Gout Market, By End User, 2018–2030 (Usd Million) 72
Table 103 Latin America: Gout Market, By Treatment And Diagnosis, 2018–2030 (Usd Million) 73
Table 104 Latin America: Gout Market, By Treatment, 2018–2030 (Usd Million) 73
Table 105 Latin America: Gout Market, By Application, 2018–2030 (Usd Million) 73
Table 106 Latin America: Gout Market, By End User, 2018–2030 (Usd Million) 73
Table 107 Major Players In The Global Gout Market 74
Table 108 Most Active Player In The Global Gout Market 77
Table 109 Product Launch/ Product Approval 78
Table 110 Partnerships/ Agreements 78
Table 111 Novartis Ag: Products Offered 81
Table 112 Lannett: Products Offered 84
Table 113 Horizon Therapeutics Plc: Products Offered 86
Table 114 Takeda Pharmaceutical Company Limited: Products Offered 89
Table 115 Glaxosmithkline Plc: Products Offered 91
Table 116 Regeneron Pharmaceuticals, Inc.: Products Offered 94
Table 117 Teijin Limited: Products Offered 96
Table 118 Viatris Inc.: Products Offered 98
Table 119 Boehringer Ingelheim International Gmbh.: Products Offered 101
Table 120 Romeg Therapeutics, Llc: Products Offered 103
Table 121 Romeg Therapeutics, Llc: Key Developments 103
List Of Figures
Figure 1 Market Synopsis 13
Figure 2 Global Gout Market 15
Figure 3 Bottom-up And Top-down Approaches 21
Figure 4 Market Dynamics: Global Gout Market 24
Figure 5 Driver Impact Analysis 26
Figure 6 Restraint Impact Analysis 28
Figure 7 Value Chain: Global Gout Market 29
Figure 8 Porter's Five Forces Analysis: Global Gout Market 31
Figure 9 Global Gout Market Share, By Diagnosis And Treatment, 2022 (%) 34
Figure 10 Global Gout Market, By Diagnosis And Treatment, 2022 (Usd Million) 34
Figure 11 Global Gout Market Share, By Treatment, 2022 (%) 35
Figure 12 Global Gout Market, By Treatment, 2022 (Usd Million) 35
Figure 13 Global Gout Market Share, By Application, 2022 (%) 40
Figure 14 Global Gout Market, By Application, 2022 (Usd Million) 40
Figure 15 Global Gout Market Share, By End User, 2022 (%) 43
Figure 16 Global Gout Market, By End User, 2022 (Usd Million) 43
Figure 17 Global: Gout Market, By Region 2022 & 2030 (Usd Million) 46
Figure 18 Global: Gout Market Share, By Region 2022 (%) 47
Figure 19 North America: Gout Market, By Country, 2022 (%) 48
Figure 20 Europe: Gout Market Share, By Country 2022 (%) 52
Figure 21 Asia-pacific: Gout Market Share, By Country, 2022 (%) 61
Figure 22 Rest Of The World: Gout Market Share, By Country, 2022 (%) 69
Figure 23 Benchmarking Of Major Competitors 75
Figure 24 Major Strategy Adopted By Key Players In The Global Gout Market 76
Figure 25 Global Gout Market: Competitive Landscape 77
Figure 26 Sales, 2022 78
Figure 27 Research & Development Expenditure, 2022 79
Figure 28 Novartis Ag: Financial Overview Snapshot 81
Figure 29 Novartis Ag: Swot Analysis 82
Figure 30 Lannett: Financial Overview Snapshot 83
Figure 31 Horizon Therapeutics Plc: Financial Overview Snapshot 86
Figure 32 Takeda Pharmaceutical Company Limited: Financial Overview Snapshot 88
Figure 33 Glaxosmithkline Plc: Financial Overview Snapshot 91
Figure 34 Glaxosmithkline Plc: Swot Analysis 92
Figure 35 Regeneron Pharmaceuticals, Inc.: Financial Overview Snapshot 93
Figure 36 Teijin Limited: Financial Overview Snapshot 95
Figure 37 Teijin Limited: Swot Analysis 96
Figure 38 Viatris Inc.: Financial Overview Snapshot 98
Figure 39 Viatris Inc: Swot Analysis 99
Figure 40 Boehringer Ingelheim International Gmbh.: Financial Overview Snapshot 101
Figure 41 Boehringer Ingelheim International Gmbh.: Swot Analysis 102

$4,950
$4,950

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings